lants, antiplatelet drugs, and prostaglandins for more than 3 months. We discussed treatment options for every patient by conference with cardiovascular specialists, nephrologists, plastic surgeons, and anesthesiologists. All patients were considered not amenable to surgical, intravascular, or other traditional treatments. Six of the 7 patients had histories of above-or below-knee or toe amputation. Anti-platelet agents, anticoagulants, and prostaglandins were continued during the pretreatment examination and follow-up, except for 1 week before the spinal anesthesia given at the time of transplantation.
Protocol
We diagnosed ASO by physical status and angiography, and assessed ischemic conditions by measuring the anklebrachial index (ABI), the toe -brachial pressure index (form PWV/ABI, Omron Colin, Tokyo), skin perfusion pressure (SPP) (PV2000, Kaneka, Osaka), and skin temperatures using thermal photography (Infraeye 1200A, Nihon Koden, Tokyo) under constant room temperature (25.0±1.0°C) and humidity (50.0±20.0%). The major and minor axes of skin ulcers were measured. These parameters were measured 0, 1, 2, 4, 12, and 24 weeks after treatment, and compared with the pretreatment values.
The patients underwent digital subtraction angiography before and 1 month after treatment. The angiographic score (2) for the formation of new collateral vessels was assessed as +0 (no collateral development), +1 (slight), +2 (moderate), and +3 (rich) at the time at which contrast flow in the main conducting arteries was most clearly visible. To minimize body temperature bias, we performed measurements at a constant room temperature and humidity, after allowing the patient to rest in the room for 15 min. Leg and toe temperatures were adjusted to forehead temperature to correct for differences in other conditions. SPP was measured on the day without HD and the value was adjusted by systemic pressure.
Patients' health-related QOL (HR-QOL) was evaluated by a questionnaire (SF-36 Health Survey, version 2 [SF-36v2]: SF-36 Medical Outcomes Trust) at 0 and 24 weeks after 
Skin temperature improved in 6 of 7 patients. Skin temperature in the lower legs and toes improved at each observational point with significance, even at 1 and 2 weeks after the treatment. The peak elevations of skin temperature were observed at 6 months after the treatment (end of the observation period) in the lower legs (+1.18±1.08°C), and 3 months in the toes (+1.33±0.92°C). *p<0.05; **p<0.01, vs control (before the treatment).
treatment. The SF-36v2 health survey consists of 36 questions that evaluate 8 discrete areas: physical functioning, social functioning, bodily pain, general health perceptions, vitality, role limitations due to emotional problems (roleemotional), role limitations due to physical health problems (role-physical), and mental health. Analysis and scoring of SF-36v2 data were subjected to norm-based scoring to compare with a Japanese standard population according to guidelines developed by Fukuhara et al. 5 
Therapies
After administration of 5 g·kg -1 ·day -1 G-CSF (lenogras- tim or filgrastim) by subcutaneous injection for 4 days, autologous PBMNCs were harvested using a Spectra cell separator (Cobe, Tokyo, Japan). We checked the number of leukocytes every day during administration of G-SCF, and if leukocyte count before administration of G-CSF was >50,000 / l, administration of G-CSF was reduced to 2.5 g· kg -1 ·day -1 , and if over 75,000 / l, administration of G-CSF was stopped. After separating PBMNCs and checking the number of CD34 + cells, patients were injected with 0.5 ml of mononuclear fluid in each of 50-100 sites in the muscle of both ischemic limbs, under epidural anesthesia on a single day. Injections were placed 1 cm apart, using a 25 g needle.
Statistical Analysis
Clinical data were analyzed with unpaired 2 group t-tests and nonparametric Mann-Whitney tests as appropriate. Results are presented as means ± SD. Analyses were performed with JMP 5.0.1J software (SAS Institute, Cary, NC, USA). P-values below 0.05 were considered to be statistically significant.
Results
In most patients, skin temperature in the lower legs and toes improved at each observational point, even at 1 and 2 weeks after the treatment (Fig 1) . The peak elevations of skin temperature were observed at 6 months after the treatment (end of the observation period) in the lower legs (+1.18±1.08°C) and at 3 months in the toes (+1.33±0.92°C). The SPP in the ankles also increased early after treatment (Fig 2) ; however, the SPP in the toes did not show a significant change. ABI also improved gradually after the treatment (Fig 3) . The peak elevation of ABI was seen at the end of the observation period (ie, 6 months: +0.11±0.15) and ABI improved more than 0.10 in 5 of 7 cases; however ABI did not show a significant change.
Ulcer size improved in 3 of 4 patients ( Table 2) . Ischemic leg pain improved in 6 of 7 patients within 2 weeks (Table 3) , and continued to the end of the observation period. Angiographic improvements were seen in 3 of 7 patients at 1 month after the treatment (Fig 4) . After treatment, bodily pain on the HR-QOL improved with significance (p<0.01) and no HR-QOL parameter got worse after the treatment (Fig 5) . We could not find any relationship between the number of CD34 + cells injected and clinical outcomes. There was no patient who had worsened ASO symptoms or ulcer size, new cardiovascular events, or other serious complications. One patient with moderate proliferative diabetic retinopathy had minor retinal bleeding 1 week after the treatment, which recovered within 1 month without functional loss. One patient with progressive toe gangrene (patient No. 5) before transplantation required toe amputation despite treatment. 
Discussion
The number of patients with ischemic limbs is increasing, especially those with DM on HD. These patients represent one of the highest risk groups for peripheral arterial disease and their treatment options are often limited to amputation. The poor outcomes of these patients may be due to vascular calcification and poor physical status. Many new angiogenetic therapeutic methods using mononuclear cells and recombinant gene therapy for ischemic limbs have been recently reported and shown to have beneficial effects. Treatment with bone marrow mononuclear cells (BMMNCs) was reported to promote angiogenesis in the diabetic foot, 2 and Rehman and Tateno reported that PBMNCs produce more angiogenic factors and cytokines than BMMNCs, which may also make them a more useful source. 6, 7 Our study also showed beneficial therapeutic effects for patients with DM on HD, which may imply an advantage of PBMNC vs BMMNC transplantation or may be related to differences in our patients' conditions. Because HD patients often have poor physical status and hypocellular bone marrow, autologous PBMNCs transplantation may be a better option because the easy blood access is less invasive. G-CSF has been reported to have some beneficial therapeutic effects for ischemic limbs. 8 In the present study, only the Fontaine IV patient with progressive gangrene and infection went on to amputation. Our other chronic Fontaine IV cases with ulcers, and the Fontaine III cases, each had a good clinical course after the therapy. Based on our data and the literature, PBMNC transplantation may be effective for chronic Fontaine III and IV ischemic limbs without infection or gangrene, although this study has the limitation of not being a control study. One patient with moderate proliferative diabetic retinopathy had minor retinal bleeding 1 week after the treatment. The oculist reported that this event was probably part of the natural course, but we can not deny the possibility that it was caused by the treatment.
No previous reports have shown the long-term effect of autologous PBMNCs transplantation nor have such effects been studied in HD patients with DM. Our data suggest that PBMNC transplantation improves leg ischemia and pain for at least 6 months and with few complications, even in such high-risk patients as those with DM on HD. In cases where amputation is required, pre-operative angiogenic therapy might prove beneficial for surgical wound healing. This therapy may also decrease the required amputation level, which often results in better QOL. This is the first study in which HR-QOL was measured in ischemic limb patients with DM on HD. We also evaluated the effect of PBMNC transplantation on certain aspects of the HR-QOL. All HR-QOL parameters before the treatment were significantly lower than in the Japanese standard population; physical functioning, physical role, and social functioning were all less than 20. These data clearly show how ASO patients with DM on HD have poor HR-QOL, and how PBMNC transplantation improved their HR-QOL, especially bodily pain.
It is still unknown whether there is a relationship between the number of CD34 + cells injected and potential improved angiogenic effects. In our study, we did not find a relationship between outcome and the number of CD34 + cells injected. For example, patient No. 2, who received 100 fewer CD34 + cells than patient No. 5, had a much bigger improvement in blood flow and ulcer condition than patient No. 5. Saigawa et al 9 and Ishida et al 4 reported that there is a positive relationship between these factors, but Kinnaird et al 10 and Rehman et al 6 reported that this benefit was related to the level of angiogenic factors produced not merely the number of cells. By examining human microvascular endothelial cells, Rookmaaker et al reported that CD34 -cells can induce migration of CD34 + cells to the endothelium because they observed little new angiogenesis and no recruitment to endothelium when CD34 cells were used alone. 11 Our results support this hypothesis. CD34 -cells might also influence angiogenesis and have therapeutic effects.
In the present study, most patients showed peripheral blood flow improvement within 1 or 2 weeks, with continued effects over 6 months. effects of cytokines after the procedure, because it is too early for significant angiogenesis to have occurred. The later, persistent effects might be because of angiogenesis, as 6 months is likely too long to sustain an acute inflammatory response. Our results suggest the hypothesis that most of the angiogenic effects are related to such angiogenic factors as interleukin (IL)-1 , PDGF, and IL-8. [12] [13] [14] [15] Therapeutic angiogenesis is an important future therapeutic target for cardiovascular and peripheral ischemic diseases. Our findings suggest long-term effects of autologous PBMNCs transplantation, not only on clinical data but also on QOL, for severe ischemic limb disease, even in diabetic patients on HD who comprise one of the highest risk groups, without serious complications.
